| Identification | More | [Name]
Naproxen sodium | [CAS]
26159-34-2 | [Synonyms]
6-METHOXY-ALPHA-METHYL-2-NAPHTHALENEACETIC ACID SODIUM
NAPROXEN SODIUM
(-)-NAPROXEN SODIUM SALT
NAPROXEN SODIUM SALT
(S)-6-METHOXY-ALPHA-METHYL-2-NAPHTHALENEACETIC ACID SODIUM SALT
(S)-6-METHOXY-A-METHYL-2-NAPHTHALENEACETIC ACID, SODIUM SALT
(S)-NAPROXEN, SODIUM SALT
(-)-SODIUM (S)-6-METHOXY-ALPHA-METHYL-2-NAPHTHALENEACETATE
6-methoxy-alpha-methyl-,sodiumsalt,(s)-2-naphthaleneaceticaci
6-methoxy-alpha-methyl-,sodiumsalt,l-(-)-2-naphthaleneaceticaci
aleve
Anaprox
apranax
l-(-)-6-methoxy-alpha-methyl-2-naphthaleneaceticacidsodiumsalt
naprosynsodium
sodiumnaprosyn
sodiumnaproxen
sodium (-)-2-(6-methoxy-2-naphthyl)propionate
Naproxen sodium USP.CP
NAPROXEN, USP | [EINECS(EC#)]
247-486-2 | [Molecular Formula]
C14H14NaO3 | [MDL Number]
MFCD00058507 | [Molecular Weight]
253.25 | [MOL File]
26159-34-2.mol |
| Chemical Properties | Back Directory | [Appearance]
White Powder | [Melting point ]
250-251°C | [alpha ]
D -11° (in methanol) | [storage temp. ]
Inert atmosphere,Room Temperature | [solubility ]
Freely soluble in water, freely soluble or soluble in methanol, sparingly soluble in ethanol (96 per cent). | [form ]
neat | [color ]
White to Off-White | [Water Solubility ]
Soluble in water up to 100mg/mlSoluble in methanol and chloroform. Slightly soluble in ether. Insoluble in water. | [Usage]
An anti-inflammatory, analgesic, antipyretic. A non-steroidal anti-inflammatory | [CAS DataBase Reference]
26159-34-2(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
R22:Harmful if swallowed. | [Safety Statements ]
53-45 | [RIDADR ]
3249 | [WGK Germany ]
3 | [RTECS ]
QJ1047000 | [HazardClass ]
6.1(b) | [PackingGroup ]
III | [HS Code ]
2918992090 |
| Questions And Answer | Back Directory | [Non-steroidal anti-inflammatory analgesic]
Naproxen sodium is a non-steroidal anti-inflammatory analgesic drug which is more tolerable to human, belonging to the phenylpropionic acid compounds. It plays anti-inflammatory effect by inhibiting prostaglandin synthesis.It is absorbed rapidly after oral administration and the plasma reached the peak concentration within 2 to 4 hours. Food has little effect on the rate of absorption. Naproxen and plasma protein are highly binded(99%); the plasma concentration is between 23~40mcg/ml. The metabolic process is demethylation and then combining with glucuronide; the elimination half-life is 12 to 15 hours, mainly excreted by the urine. Clinical application is to relieve a variety of mild to moderate degree of pain, such as tooth extraction and other postoperative pain, primary dysmenorrhea and headache. It is also used for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, juvenile arthritis, tendinitis, bursitis and acute gouty arthritis; it also plays a role in arthritis pain, swelling and activity restricted symptom. Psoriatic arthritis and Reiter's syndrome can also be treated with this product. Compared with ibuprofen, fenoprofen, aspirin, sulindac and indomethacin, the symptom relief effect was similar, but the incidence and severity of adverse reactions in the gastrointestinal and neurological systems were low. In addition, this product is also the same as aspirin which can inhibit platelet aggregation and prolong bleeding time; but the effect is reversible, and can be restored after stopping.
Naproxen sodium and plasma protein binding rate is high (99%), and other protein-binding drugs can be replaced by its joint out. Therefore, the acceptance of these drugs (such as oral anticoagulants, sulfonylurea, hydantoins) people should observe the interaction effects. At the same time the application of probenecid, naproxen can increase the plasma concentration, half-life period. Magnesium hydroxide, aluminum can make this product absorption rate slightly lower; sodium bicarbonate can make it higher. | [Uses]
Used as anti-inflammatory analgesic |
| Hazard Information | Back Directory | [Chemical Properties]
White Powder | [Definition]
ChEBI: The sodium salt of naproxen. | [Brand name]
Aleve (Bayer); Anaprox (Roche);Naprelan (Stat Trade). | [General Description]
Naproxen sodium (NS) is a sodium salt of propionic acid derivative and demonstrates analgesic, anti-pyretic, and anti-inflammatory properties. It exhibits efficiency in being used as an indomethacin in the treatment of acute musculoskeletal disorders. It belongs to the group of nonsteroidal anti-inflammatory drugs (NSAIDS) and acts by inhibiting the activity of both the cyclooxygenase enzymes, COX-1 & COX-2 and further blocking the synthesis of certain prostaglandins. It is administered in the treatment of ankylosing spondylitis, osteoarthritis, rheumatoid disorders, acute gout, mild to moderate pain, tendonitis, bursitis, dysmenorrhea, fever, and migraine headache. Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. | [Biological Activity]
Non-selective cyclooxygenase (COX) inhibitor that displays anti-inflammatory, antipyretic and analgesic effects. Has a neuroprotective role against colchicine-induced cognitive impairment and oxidative stress. | [Biochem/physiol Actions]
Cyclooxygenase (Prostaglandin H synthase 1 and 2) inhibitor. | [References]
[1]. mendias cl, tatsumi r and allen re. role of cyclooxygenase-1 and -2 in satellite cell proliferation, differentiation, and fusion. muscle nerve, 2004, 30(4):497-500.
[2]. hinz b, cheremina o, besz d, et al. impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. int j clin pharmacol ther, 2008, 46(4):180-6.
[3]. sances g, martignoni e, fioroni l, et al. naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. headache, 1990, 30(11):705-9.
[4]. tavolari s, bonafè m, marini m, et al. licofelone, a dual cox/5-lox inhibitor, induces apoptosis in hca-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. carcinogenesis, 2008, 29(2):371-80. |
|
|